Done ADHD Investigation Sparks Worry of Inadequate Care

June 25, 2024

Earlier this month, the Justice Department charged two top officers at the telehealth company Done Global with allegedly distributing Adderall and other stimulants for ADHD to patients who officials said did not merit a proper diagnosis. While health officials warned that the “disruption” to Done could affect as many as 50,000 adult patients¹, many of whom were already impacted by the ongoing ADHD medication shortage, this criminal action highlights another important issue: the limited access to clinical care for people with ADHD in the United States.

“When a company such as Done is held legally responsible and their policies are investigated, patients under clinicians’ care may lose their prescriber, leaving them abandoned without medical care,” says David Goodman, M.D., an assistant professor in psychiatry and behavioral sciences at the Johns Hopkins School of Medicine.

“The immediate need for medication is not easily resolved because changing providers typically involves a delay. Without effective medication, patients’ daily performance is compromised and may lead to conflicts at home or reduced work productivity,” Goodman says. “The negative consequences mount the longer they are off their medication.”

Rise and Fall of ADHD Telehealth

Done and other ADHD telehealth services surged in popularity during the COVID pandemic as Americans in lockdown were unable to schedule in-person doctor visits. At the same time, the Drug Enforcement Administration (DEA) loosened telemedicine rules regulating the prescription and distribution of controlled substances, including stimulants to treat ADHD.

“Done came out of real patient pain points, including access and wait times” for clinical care, says Jacob Behrens, M.D., CEO of Envision ADHD Clinic. “They expanded as they did for a number of reasons, including how poorly our health care system met the needs of this particular population. This issue is and has been real since well before the pandemic.”

Of the 30,000 to 50,000 patients who used Done and may be seeking new providers, Behrens said: “I can’t begin to imagine how the existing health care system will absorb this population. I’m just hoping that we can use this as an educational opportunity for a deeper dive/postmortem analysis of in what ways did this improve patient care and where did it go wrong?”

Maggie Sibley, Ph.D., a psychologist, researcher, and author, suggested that the Done investigation into fraudulent stimulant prescription practices might actually help alleviate the stimulant shortage for patients with ADHD.

“If many Done clients were filling Adderall prescriptions for non-medical reasons, then presumably they were taking medications that should have gone to people with ADHD,” she says. “Eliminating the non-legitimate use of stimulants might hopefully help with the demand side of the stimulant shortage. People will be able to get their medications more easily because they are reserved for people who truly have ADHD.”

ADHD Treatment Alternatives

Greg Mattingly, M.D., an associate clinical professor at Washington University School of Medicine, says he is hopeful that improved ADHD awareness and education, overall, will mean that patients ask their providers about new medications like Xelstrym, Jornay PM, and Azstarys, which are not experiencing the shortfalls that have dogged Adderall and Vyvanse. Patients who understand the full spectrum of ADHD treatment options may be more likely to access care during the ongoing stimulant shortage.

“The rising number of prescriptions during the past several years² has caught the DEA’s attention,” says Ann Childress, past president of the American Professional Society of ADHD and Related Disorders (APSARD). The DEA sets quotas for the production of controlled substances in the United States and is widely criticized for failing to allow enough production of stimulant medication to keep pace with new diagnoses.

“We are still dealing with a stimulant shortage, and I am still having to switch patients’ medications because their regular medication is not available,” Childress says. “Most clinicians that I speak with are having the same difficulties. Several medications that are not controlled substances are approved for the treatment of ADHD by the FDA. Patients may want to discuss these medications with their providers.”

Goodman advised that some hospital pharmacies may fill prescriptions for hard-to-find stimulant medications if those stimulants are ordered by an affiliated provider. He suggested that patients inquire with their providers about this option, as hospital pharmacies may experience less patient demand than neighborhood or chain pharmacies like CVS or Walgreens.

“Hospitals that have public community pharmacies can typically fill the same prescriptions that any other community pharmacy can fill,” says Aretha L. Hankinson, J.D., director of media relations for the American Society of Health-System Pharmacists. “They generally also experience the same allocations and shortages as other community pharmacies.”

View Article Sources

• Facebook
• Twitter
• Instagram
• Pinterest